Cardiff Oncology, Inc. (CRDF)
| Market Cap | 115.19M |
| Revenue (ttm) | 593,000 |
| Net Income (ttm) | -45.88M |
| Shares Out | 68.36M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 512,619 |
| Open | 1.720 |
| Previous Close | 1.720 |
| Day's Range | 1.675 - 1.740 |
| 52-Week Range | 1.480 - 4.555 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 9.63 (+471.51%) |
| Earnings Date | May 7, 2026 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR... [Read more]
Financial Performance
In 2025, Cardiff Oncology's revenue was $593,000, a decrease of -13.18% compared to the previous year's $683,000. Losses were -$45.88 million, 0.93% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price target is $9.63, which is an increase of 471.51% from the latest price.
News
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range...
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announce...
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for...
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer Appoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Ope...
Cardiff Oncology Transcript: KOL event
KOLs reviewed promising phase II data for onvansertib plus FOLFIRI+BEV in first-line RAS mutated metastatic CRC, highlighting a 72% response rate, strong PFS trends, and favorable tolerability. The 30 mg dose will advance to phase III, addressing a major unmet need for this patient group.
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibition Preclinical results in therapy-resistant ...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Onvansertib, a selective PLK1 inhibitor, demonstrated a 72% ORR and promising PFS in first-line RAS-mutated mCRC, with no significant added toxicity. Plans are underway for a global phase III trial, with regulatory discussions and more data expected in the first half of the year.
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FO...
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus
Cardiff Oncology Inc. (NASDAQ: CRDF) on Tuesday closed around 32% lower after the management update and trial update.
Cardiff Oncology Transcript: Study result
Promising phase II data show that onvansertib plus FOLFIRI-Bev achieved a 72.2% response rate and extended PFS in first-line RAS-mutated mCRC, with favorable safety. The 30 mg dose will advance to a registrational trial, with further data and regulatory updates expected in 2026.
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in pat...
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology Transcript: Sidoti's Year End Virtual Investor Conference
Onvansertib demonstrates robust efficacy and safety in RAS-mutated metastatic colorectal cancer, with strong early clinical results and FDA-aligned plans for a registrational trial. Strategic partnerships and a solid cash position support continued progress and market potential.
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology Transcript: Piper Sandler 37th Annual Healthcare Conference
Onvansertib, a selective oral PLK1 inhibitor, showed promising efficacy and safety in phase II for RAS-mutated metastatic colorectal cancer, with a 19% higher response rate at the optimal dose and no significant added toxicity. Plans include a phase III trial and data update in Q1 next year.
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference
Onvansertib shows promising efficacy and safety in first-line RAS-mutated metastatic colorectal cancer, with higher response rates and deep tumor shrinkage at the 30 mg dose. A seamless phase 3 trial is planned, and the next major data update is expected in Q1 next year.
Cardiff Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Onvansertib, a selective PLK1 inhibitor, is showing promising efficacy and safety in first-line RAS-mutated metastatic CRC, with key data expected in Q1 2026. The program targets a large unmet need, with a strong market opportunity and additional pipeline potential.
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to repo...
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...